Filtered By:
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 1818 results found since Jan 2013.

Left atrial appendage closure for stroke prevention in atrial fibrillation : An update.
Authors: Zimmermann F, Landmesser U Abstract Atrial fibrillation (AF) is one of the most frequent causes of ischemic stroke. Without treatment the annual risk of ischemic stroke is on average approximately 5-6%/year in patients with atrial fibrillation, depending on the overall cardiovascular risk profile. Oral anticoagulation with new oral anticoagulants (NOAC) or vitamin K antagonists (VKA) is recommended for patients with AF and an elevated risk for stroke (CHA2DS2-VASc score ≥1); however, severe bleeding complications are potential reasons for discontinuation of this treatment. Overall, up to 30 % of the pa...
Source: Herz - May 18, 2020 Category: Cardiology Tags: Herz Source Type: research

Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.
Abstract INTRODUCTION: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly used in the elderly with AF at high risk for stroke and bleeding and with comorbidities requiring polypharmacy, it is important to assess their safety and efficacy in this population. AREAS COVERED: We review changes in pharmacokinetics and pharmacodynamics observed with senescence and the effect on NOACs and drug and food interactions. We also provide an update on challenges related to NOAC use in situations that incre...
Source: Pharmacological Reviews - October 27, 2020 Category: Drugs & Pharmacology Authors: Ajam T, Cumpian TL, Tilkens BL, Jahangir IA, Frost J, Ceretto C, Jahangir A Tags: Expert Rev Clin Pharmacol Source Type: research

Analysis of Influencing Factors of Compliance with Non-Vitamin K Antagonist Oral Anticoagulant in Patients with Nonvalvular Atrial Fibrillation and Correlation with the Severity of Ischemic Stroke
In this study, a total of 156 patients with NVAF who received NOAC anticoagulation therapy in our hospital from January 2018 to January 2019 were retrospectively analyzed. The results showed that education background, place of residence, number of complications, CHA2DS2-VASc score, and HAS-BLED score were independent influencing factors for NOACS compliance of NVAF patients. Also, the Pearson correlation analysis showed that there was a negative correlation (r = -0.465, P < 0.001) between NOAC compliance and severity of ischemic stroke in patients with NVAF. Therefore, clinical supervision and management of patients wit...
Source: Evidence-based Complementary and Alternative Medicine - October 29, 2021 Category: Complementary Medicine Authors: Li Zhu Xiaodan Zhang Jing Yang Source Type: research

Impact of type of oral anticoagulants in patients with cerebral microbleeds after atrial fibrillation-related ischemic stroke or TIA: Results of the NOACISP-LONGTERM registry
ConclusionsIn AF-stroke patients treated with OAC, the presence of CMBs was associated with an unfavorable composite outcome for both VKAs and DOACs, with a higher risk for recurrent IS than for ICH. Strokes were numerically higher under VKAs and increased in the presence of CMBs.Clinical trial registrationhttp://www.clinicaltrials.gov, Unique identifier: NCT03826927.
Source: Frontiers in Neurology - September 20, 2022 Category: Neurology Source Type: research

Left ventricular thrombus in a patient with recurrent ischemic stroke events —The role of echocardiography
We present a patient with an ischemic stroke, and the cardiac ultrasound revealed a reduced ejection fraction and the presence of LV thrombus at the apex. The patient had no prior history of cardiovascular diseases. Even in a resource-limited setting, cardiac ultrasound is recommended to investigate stroke or transient ischemic attack events, especially in patients with a prior history of myocardial infarction. Although patients with LV thrombus should be treated with oral anticoagulants for at least 3  months, the role of direct oral anticoagulants and the optimal period of anticoagulation in this setting needs further investigation.
Source: Clinical Case Reports - May 2, 2023 Category: General Medicine Authors: Vasiliki Vanesa Stylianou, Vasiliki Tsampasian, Marios Pavlou, Panagiota Georgiou, Dimitrios Patestos, Lorentzos Kapetis, Vassilios S. Vassiliou, Christos Eftychiou, Michalis Tsielepis, George Bazoukis Tags: CASE REPORT Source Type: research

Acute reperfusion treatment and secondary prevention of cancer-related stroke: comprehensive overview and proposal of clinical algorithm
In conclusion, acute CRS remains a clinical challenge, with many patients suffering recurrent stroke, despite preventive measures. More randomized-controlled clinical trials are urgently needed to pinpoint the most effective management options for this subset of stroke patients.PMID:37342814 | PMC:PMC10278431 | DOI:10.1177/17562864231180717
Source: Adv Data - June 21, 2023 Category: Epidemiology Authors: Athina-Maria Aloizou Lina Palaiodimou Dimitra Aloizou Efthimios Dardiotis Ralf Gold Georgios Tsivgoulis Christos Krogias Source Type: research

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective.
CONCLUSION: This study suggests that the use of dabigatran in French atrial fibrillation patients is cost-effective, according to usually accepted thresholds. PMID: 24973113 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - June 24, 2014 Category: Cardiology Authors: Chevalier J, Delaitre O, Hammès F, de Pouvourville G Tags: Arch Cardiovasc Dis Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Non-vitamin K antagonist oral anticoagulants (NOACs) are frequently used to prevent stroke in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet agents. It is possible that treatment with both NOACs and aspirin or other antiplatelet drug may be effective in decreasing stroke, but data are sparse regarding the efficacy and safety of using both agents for stroke prevention. To address these issues, data were pooled from the 4 recent randomized, controlled trials of NOACs: apixaban, rivaroxaban, dabigatran, and edoxaban, which included 42,411 patients; 14,148 (33.4%) were also on...
Source: Cardiology in Review - August 9, 2016 Category: Cardiology Tags: Review Articles Source Type: research

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
ConclusionsOur case report adds to the evidence that idarucizumab administration is safe in the setting of patients with atrial fibrillation treated with dabigatran who develop acute ischemic stroke requiring thrombolysis.
Source: Journal of Medical Case Reports - August 15, 2017 Category: General Medicine Source Type: research

Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
ConclusionThis population-based cohort study of routine care indicates similar or better effectiveness and safety with NOAC compared with warfarin treatment. NOACs were associated with fewer intracranial bleeds, but more gastrointestinal bleeds.
Source: Europace - February 10, 2017 Category: Cardiology Source Type: research

Atrial Fibrillation had Less Impact on the Risk of Ischemic Stroke in Non-anticoagulated Patients Undergoing Hemodialysis: Insight from the RAKUEN study.
Conclusion A great impact on death, but not ischemic stroke, was observed in non-anticoagulated hemodialysis patients with AF in comparison to those without AF from the analysis of the RAKUEN study. PMID: 29607945 [PubMed - as supplied by publisher]
Source: Internal Medicine - April 4, 2018 Category: Internal Medicine Tags: Intern Med Source Type: research

Impact of NOACs on Ischemic Stroke Severity in AF Impact of NOACs on Ischemic Stroke Severity in AF
Can the use of non-vitamin K-dependent oral anticoagulants prior to stroke onset in patients with atrial fibrillation reduce the severity of stroke, if ischemic stroke should occur?Europace
Source: Medscape Today Headlines - May 11, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study
This study is registered with ClinicalTrials.gov, number NCT02513316. Findings Between Aug 4, 2011, and July 31, 2015, we recruited 1490 participants of whom follow-up data were available for 1447 (97%), over a mean period of 850 days (SD 373; 3366 patient-years). The symptomatic intracranial haemorrhage rate in patients with cerebral microbleeds was 9·8 per 1000 patient-years (95% CI 4·0–20·3) compared with 2·6 per 1000 patient-years (95% CI 1·1–5·4) in those without cerebral microbleeds (adjusted hazard ratio 3·67, 95% CI 1·27–10·60). Compared with the HAS-BLED score alone (C-index 0·41, 95% CI 0·29–0Â...
Source: The Lancet Neurology - May 16, 2018 Category: Neurology Source Type: research